Abstract:Future Medicinal ChemistryVol. 11, No. 15 EditorialNovel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitorsXuewu Liang, Hong Liu & Yingjie ZhangXuewu LiangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmacy, Shandong University, Shandong, 250012, PR ChinaState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, PR ChinaSearch for more papers by this author, Hong Liu**Author for correspondence: E-mail Address: hliu@mail.shcnc.ac.cnState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, PR ChinaSearch for more papers by this author & Yingjie Zhang*Author for correspondence: E-mail Address: zhangyingjie@sdu.edu.cnDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmacy, Shandong University, Shandong, 250012, PR ChinaSearch for more papers by this authorPublished Online:13 Sep 2019https://doi.org/10.4155/fmc-2019-0168AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: dual inhibitorsHDAChematological malignanciesJAKmultiple target drugsReferences1. Qianwen Gao, Xuewu Liang, Abdul Sami Shaikh et al. JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases. Curr. Drug Targets 19(5), 487–500 (2018).Crossref, Medline, Google Scholar2. Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 11(20), 2819–2830 (2015).Crossref, Medline, CAS, Google Scholar3. Nairismägi ML, Gerritsen ME, Li ZM et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia 32, 1147–1156 (2018).Crossref, Medline, CAS, Google Scholar4. Bellanger D, Jacquemin V, Chopin M et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28(2), 417–419 (2014).Crossref, Medline, CAS, Google Scholar5. Prutsch N, Gurnhofer E, Suske T et al. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia 33(3), 696–709 (2019).Crossref, Medline, CAS, Google Scholar6. Sangwan R, Rajan R, Mandal PK. HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors. Eur. J. Med. Chem. 158, 620–706 (2018).Crossref, Medline, CAS, Google Scholar7. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280(2), 168–176 (2009).Crossref, Medline, CAS, Google Scholar8. Fantin VR, Loboda A, Paweletz CP et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68(10), 3785–3794 (2008).Crossref, Medline, CAS, Google Scholar9. Koppikar P, Bhagwat N, Kilpivaara O et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489(7414), 155–159 (2012).Crossref, Medline, CAS, Google Scholar10. Guerini V, Barbui V, Spinelli O et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 22(4), 740–747 (2008).Crossref, Medline, CAS, Google Scholar11. Wang Y, Fiskus W, Chong DG et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 114(24), 5024–5033 (2009).Crossref, Medline, CAS, Google Scholar12. Novotny-Diermayr V, Hart S, Goh KC et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2(5), e69 (2012).Crossref, Medline, CAS, Google Scholar13. Harrison CN, Jean-Jacques Kiladjian, Heidel FH et al. Efficacy, safety, and confirmation of the recommended Phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (Pts) with myelofibrosis (MF). Blood 126, 4060 (2015).Crossref, Google Scholar14. Liang X, Zang J, Li X et al. Discovery of novel janus kinase (JAK) and histone deacetylase (HDAC) dual inhibitors for the treatment of hematological malignancies. J. Med. Chem. 62(8), 3898–3923 (2019).Crossref, Medline, CAS, Google Scholar15. Yang EG, Mustafa N, Tan EC et al. Design and synthesis of janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines. J. Med. Chem. 59(18), 8233–8262 (2016).Crossref, Medline, CAS, Google Scholar16. Yao L, Mustafa N, Tan EC et al. Design and synthesis of ligand efficient dual inhibitors of janus kinase (JAK) and histone deacetylase (HDAC) based on ruxolitinib and vorinostat. J. Med. Chem. 60(20), 8336–8357 (2017).Crossref, Medline, CAS, Google Scholar17. Chu-Farseeva YY, Mustafa N, Poulsen A et al. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. Eur. J. Med. Chem. 158, 593–619 (2018).Crossref, Medline, CAS, Google Scholar18. Huang Y, Dong G, Li H et al. Discovery of janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors as a novel strategy for the combinational treatment of leukemia and invasive fungal infections. J. Med. Chem. 61(14), 6056–6074 (2018).Crossref, Medline, CAS, Google Scholar19. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery: miniperspective. J. Med. Chem. 57, 7874–7887 (2014).Crossref, Medline, CAS, Google Scholar20. Zeng H, Qu J, Jin N et al. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer. Cancer Cell 30(3), 459–473 (2016).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByFunctional stratification of cancer drugs through integrated network similarity19 April 2022 | npj Systems Biology and Applications, Vol. 8, No. 1New kinase and HDAC hybrid inhibitors: recent advances and perspectivesKaroline Waitman & Roberto Parise-Filho11 May 2022 | Future Medicinal Chemistry, Vol. 14, No. 10Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathwayEuropean Journal of Medicinal Chemistry, Vol. 229Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors15 February 2021 | Journal of Medicinal Chemistry, Vol. 65, No. 2Synthesis, anticancer activity, SAR and binding mode of interaction studies of substituted pentanoic acids: part IISanchita Datta, Amit Kumar Halder, Nilanjan Adhikari, Sk Abdul Amin, Sanjib Das & Tarun Jha25 November 2021 | Future Medicinal Chemistry, Vol. 14, No. 1Meet Our Editorial Board MemberAnti-Cancer Agents in Medicinal Chemistry, Vol. 21, No. 9 Vol. 11, No. 15 Follow us on social media for the latest updates Metrics Downloaded 173 times History Received 27 May 2019 Accepted 5 June 2019 Published online 13 September 2019 Published in print August 2019 Information© 2019 Newlands PressKeywordsdual inhibitorsHDAChematological malignanciesJAKmultiple target drugsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download

Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor‐naïve Patients with Myelofibrosis: Results of a Phase II Trial

Dual-target Janus Kinase (JAK) Inhibitors: Comprehensive Review on the JAK-based Strategies for Treating Solid or Hematological Malignancies and Immune-Related Diseases.

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents

Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors As a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.

Novel Hybrid Molecule Overcomes the Limited Response of Solid Tumours to HDAC Inhibitors Via Suppressing JAK1-STAT3-BCL2 Signalling

Discovery of Novel Pazopanib-based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

Novel-targeted Therapy for Hematological Malignancies with JAK and HDAC Dual Inhibitors

Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer

Discovery of Epigenetic Modulators Targeting Hdacs and Ezh2 Simultaneously for the Treatment of Hematological Malignancies

Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors As a Promising Strategy for Cancer Therapy.

Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity Against Triple Negative Breast Cancer.

A JAK Tyrosine Kinase and Pseudokinase Co-inhibition Strategy Combines Enhanced Potency and On-Demand Activation

Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit